Richard Klar

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 4

Top Topics

Peritoneal Dialysis

Highly Efficient

Top Venues

Cancer immunology, immunotherapy : CII

Nucleic acid therapeutics

Journal of immunology (Baltimore, Md. : 1950)

Molecular diagnosis & therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Benedikt Kaufmann, Marta de Los Reyes Jiménez, Laela M Booshehri, Janset Onyuru, Aleksandra Leszczynska, Anna Uri, Sven Michel, Richard Klar, Frank Jaschinski, Ariel E Feldstein, Lori Broderick, Hal M Hoffman
Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice. Journal of immunology (Baltimore, Md. : 1950) (2023)
Sven Michel, Richard Klar, Frank Jaschinski
Investigation of the Activity of Antisense Oligonucleotides Targeting Multiple Genes by RNA-Sequencing. Nucleic acid therapeutics (2021)
Sven Michel, Ksenija Schirduan, Yimin Shen, Richard Klar, Jorg Tost, Frank Jaschinski
Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines. Molecular diagnosis & therapy 25 (1) (2020)
Richard Klar, Sven Michel, Monika Schell, Lisa Hinterwimmer, Alfred Zippelius, Frank Jaschinski
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Cancer immunology, immunotherapy : CII 69 (1) (2019)